Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/ Pharmacodynamics, and Antitumor Activity of TGI-6 as Monotherapy in Subjects With Locally Advanced/Metastatic Solid Tumors

Next Previous
Trial Profile

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/ Pharmacodynamics, and Antitumor Activity of TGI-6 as Monotherapy in Subjects With Locally Advanced/Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TGI-6 (Primary)
  • Indications Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Oesophageal cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors TG ImmunoPharma

Most Recent Events

  • 16 Apr 2024 Planned End Date changed to 1 Dec 2027.
  • 16 Apr 2024 Planned primary completion date changed to 1 Sep 2027.
  • 16 Apr 2024 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top